Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
Reported Earlier, MediciNova Receives Notice Of Allowance From Japan Patent Office For MN-166 In Macular Injury Treatment
早些时候报道，MediciNova 收到了日本专利局批准黄斑损伤治疗的 MN-166 的通知
Once issued, this patent is expected to expire no earlier than October 2039. The allowed claims cover the use of MN-166 (ibudilast) for treating macular injury associated with progressive multiple sclerosis and for decreasing macular volume loss associated with progressive multiple sclerosis.
该专利一旦颁发，预计将不早于2039年10月到期。允许的索赔涵盖使用 MN-166（ibudilast）治疗与进行性多发性硬化症相关的黄斑损伤以及减少与进行性多发性硬化症相关的黄斑体积流失。